Plain English summary
Background
Methods
Study participants and design
The intervention
Health-related quality of life measurements
Sociodemographic and comorbidity data
Statistical analysis
Results
Characteristics of the study population
Full population | Non-long stayers | Long stayers | |||||||
---|---|---|---|---|---|---|---|---|---|
Intervention group (N = 148) | Control group (N = 137) | Total (N = 285) | Intervention group (N = 106) | Control group (N = 116) | Total (N = 222) | Intervention group (N = 42) | Control group (N = 21) | Total (N = 63) | |
Age, years | |||||||||
Mean (SD) | 82.8 (6.0) | 82.1 (5.9) | 82.5 (6.0) | 82.4 (6.1) | 81.9 (5.9) | 82.2 (6.0) | 83.9 (5.9) | 82.9 (6.1) | 83.5 (5.9) |
70–74 years, n (%)a | 16 (10.8) | 21 (15.3) | 37 (13.0) | 12 (11.3) | 19 (16.4) | 31 (14.0) | 4 (9.5) | 2 (9.5) | 6 (9.5) |
75–79 years, n (%)a | 27 (18.2) | 24 (17.5) | 51 (17.9) | 20 (18.9) | 19 (16.4) | 39 (17.6) | 7 (16.7) | 5 (23.8) | 12 (19.1) |
80–84 years, n (%)a | 44 (29.7) | 42 (30.7) | 86 (30.2) | 32 (30.2) | 39 (33.6) | 71 (32.0) | 12 (28.6) | 3 (14.3) | 15 (23.8) |
≥ 85 years, n (%)a | 61 (41.2) | 50 (36.5) | 111 (39.0) | 42 (39.6) | 39 (33.6) | 81 (36.5) | 19 (45.2) | 11 (52.4) | 30 (47.6) |
Sex, n (%) | |||||||||
Female | 74 (54.0) | 98 (66.2) | 172 (60.4) | 69 (65.1) | 65 (56.0) | 134 (60.4) | 29 (69.1) | 9 (42.9) | 38 (60.3) |
Level of education, n (%) | |||||||||
Low (< 12 years) | 75 (52.8) | 73 (54.1) | 148 (53.4) | 52 (49.1) | 64 (55.2) | 116 (52.3) | 23 (54.8) | 9 (42.9) | 32 (50.8) |
High (> 12 years) | 67 (47.2) | 62 (45.9) | 129 (46.6) | 50 (47.2) | 50 (43.1) | 100 (45.1) | 17 (40.5) | 12 (57.1) | 29 (46.0) |
Missing | 6 (4.1) | 2 (1.5) | 8 (2.8) | 4 (3.8) | 2 (1.7) | 6 (2.7) | 2 (4.8) | 0 (0.0) | 2 (3.2) |
Living status, n (%) | |||||||||
Home-dwelling before included | 137 (92.6) | 129 (94.2) | 266 (93.3) | 100 (94.3) | 111 (95.7) | 211 (95.1) | 37 (88.1) | 18 (85.7) | 55 (87.3) |
Living alone before included | 86 (58.5) | 82 (59.9) | 168 (59.2) | 59 (56.2) | 69 (59.5) | 128 (57.9) | 27 (64.3) | 13 (61.9) | 40 (63.5) |
Discharged home | 113 (76.4) | 101 (74.3) | 214 (75.4) | 91 (85.9) | 91 (78.5) | 182 (82.0) | 22 (52.4) | 10 (50.0) | 32 (51.6) |
Need for assistance, n (%) | |||||||||
Home-care services | 75 (50.7) | 77 (56.2) | 152 (53.3) | 48 (45.3) | 63 (54.3) | 111 (50.0) | 27 (64.3) | 14 (66.7) | 41 (65.1) |
Multidose adherence aid | 43 (29.0) | 48 (35.0) | 91 (31.9) | 28 (25.5) | 38 (32.8) | 65 (29.3) | 16 (38.1) | 10 (47.6) | 26 (41.3) |
Handling own medications | 77 (52.0) | 64 (46.7) | 141 (49.5) | 59 (55.7) | 58 (50.0) | 117 (52.7) | 18 (42.9) | 6 (28.6) | 24 (38.1) |
Medication use, admission, mean (SD) | |||||||||
Number of medications regular use | 6.6 (4.0) | 7.4 (4.0) | 7.0 (4.0) | 6.8 (4.1) | 7.2 (4.0) | 7.0 (4.0) | 6.4 (3.9) | 8.5 (3.9) | 7.1 (4.0) |
Number of medications total | 8.7 (5.1) | 9.6 (5.4) | 9.1 (5.2) | 8.8 (5.1) | 9.4 (5.4) | 9.1 (5.3) | 8.5 (5.1) | 10.5 (5.1) | 9.1 (5.2) |
Medications total < 5, n (%)a | 31 (21.0) | 23 (16.8) | 54 (19.0) | 20 (18.9) | 22 (19.0) | 42 (18.9) | 11 (26.2) | 1 (4.8) | 12 (19.1) |
Medications total ≥ 5, n (%)a | 117 (79.1) | 114 (83.2) | 231 (81.1) | 86 (81.1) | 94 (81.0) | 180 (81.1) | 31 (73.8) | 20 (95.2) | 51 (81.0) |
Medication use, discharge, mean (SD) | |||||||||
Number of medications regular use | 7.0 (3.6) | 7.6 (3.8) | 7.3 (3.7) | 6.9 (3.5) | 7.5 (3.9) | 7.2 (3.7) | 7.3 (3.8) | 8.1 (3.4) | 7.6 (3.6) |
Number of medications total | 10.3 (5.0) | 10.4 (5.5) | 10.3 (5.2) | 10.2 (5.0) | 10.3 (5.6) | 10.2 (5.3) | 10.8 (5.0) | 10.7 (4.5) | 10.7 (4.8) |
Medications total < 5, n (%)a | 16 (10.8) | 16 (11.7) | 32 (11.2) | 12 (11.3) | 15 (12.9) | 27 (12.2) | 4 (9.5) | 1 (4.8) | 5 (7.9) |
Medications total ≥ 5, n (%)a | 132 (89.2) | 121 (88.3) | 253 (88.8) | 94 (88.7) | 101 (87.1) | 195 (87.8) | 38 (90.5) | 20 (95.2) | 58 (92.1) |
Charlson Comorbidity Index, mean (SD) | 2.1 (1.8) | 2.5 (2.0) | 2.3 (1.9) | 2.1 (1.8) | 2.4 (2.0) | 2.3 (1.9) | 2.2 (1.7) | 3.0 (1.7) | 2.5 (1.7) |
Comorbidities in admission notes, n (%) | |||||||||
Hypertension | 75 (51.7) | 69 (50.4) | 144 (50.5) | 54 (50.9) | 58 (50.0) | 110 (49.6) | 21 (50.0) | 11 (52.4) | 32 (50.8) |
Asthma or COPD | 44 (29.7) | 38 (27.7) | 82 (28.8) | 34 (32.1) | 33 (28.5) | 67 (30.2) | 10 (23.8) | 5 (23.8) | 15 (23.8) |
Atrial fibrillation | 37 (25.0) | 42 (30.7) | 79 (27.7) | 25 (23.6) | 36 (31.0) | 61 (27.5) | 12 (28.6) | 6 (28.6) | 18 (28.6) |
Diabetes | 28 (18.9) | 31 (22.6) | 59 (20.7) | 21 (19.8) | 25 (21.6) | 46 (20.7) | 7 (16.7) | 6 (28.6) | 13 (20.6) |
Heart failure | 24 (16.2) | 21 (15.3) | 45 (15.8) | 14 (13.2) | 17 (14.7) | 31 (14.0) | 10 (23.8) | 4 (19.1) | 14 (22.2) |
Renal failure | 24 (16.2) | 21 (15.3) | 45 (15.8) | 14 (13.2) | 16 (13.8) | 30 (13.5) | 4 (9.5) | 0 (0.0) | 4 (6.4) |
Anxiety/depression | 17 (11.5) | 11 (8.0) | 28 (9.8) | 11 (10.4) | 10 (8.6) | 21 (9.5) | 10 (23.8) | 5 (23.8) | 15 (23.8) |
Dementia | 7 (4.7) | 4 (2.9) | 11 (3.9) | 3 (2.8) | 4 (3.5) | 7 (3.2) | 4 (9.5) | 0 (0.0) | 4 (6.4) |
Died during the study period, n (%) | 14 (9.5) | 12 (8.8) | 26 (9.1) | 7 (6.6) | 10 (8.6) | 17 (7.7) | 7 (16.7) | 2 (9.5) | 9 (14.3) |
Study ward, n (%) | |||||||||
Ward 1 | 117 (79.1) | 103 (75.2) | 220 (77.2) | 80 (75.5) | 85 (73.3) | 165 (74.3) | 37 (88.1) | 18 (85.7) | 55 (87.3) |
Ward 2 | 31 (21.0) | 34 (24.8) | 65 (22.8) | 26 (24.5) | 31 (26.7) | 57 (25.7) | 5 (11.9) | 3 (14.3) | 8 (12.8) |
EQ-5D-3L dimensions
Discharge N = 285 | 1 month N = 277 | 6 months N = 268 | 12 months N = 259 | |||||
---|---|---|---|---|---|---|---|---|
Intervention group n = 148 | Control group n = 137 | Intervention group n = 145 | Control group n = 132 | Intervention group n = 139 | Control group n = 129 | Intervention group n = 134 | Control group n = 125 | |
Mobility, n (%) | ||||||||
No problems | 35 (24.0) | 32 (23.4) | 41 (28.3) | 29 (22.0) | 35 (25.2) | 23 (17.8) | 30 (22.2) | 18 (14.4) |
Moderate problems | 101 (69.2) | 92 (67.2) | 86 (59.3) | 86 (65.2) | 83 (59.7) | 85 (65.9) | 72 (53.3) | 79 (63.2) |
Extreme problems | 10 (6.9) | 13 (9.5) | 8 (5.5) | 7 (5.3) | 4 (2.9) | 8 (6.2) | 10 (7.4) | 9 (7.2) |
Reporting some problemsa | 111 (75.0) | 105 (76.6) | 94 (64.8) | 93 (70.5) | 87 (62.6) | 93 (72.1) | 82 (60.7) | 88 (70.4) |
Missing | 2 (1.4) | 0 (0) | 10 (6.9) | 10 (7.6) | 17 (12.2) | 13 (10.1) | 23 (17.0) | 19 (15.2) |
Self-care, n (%) | ||||||||
No problems | 93 (63.7) | 83 (60.6) | 87 (60.0) | 85 (64.4) | 95 (68.4) | 84 (65.1) | 77 (57.0) | 78 (62.4) |
Moderate problems | 43 (29.5) | 36 (26.3) | 42 (29.0) | 29 (22.0) | 22 (15.8) | 24 (18.6) | 29 (21.5) | 19 (15.2) |
Extreme problems | 10 (6.9) | 18 (13.1) | 6 (4.1) | 8 (6.1) | 5 (3.6) | 7 (5.4) | 6 (4.4) | 9 (7.2) |
Reporting some problemsa | 53 (35.8) | 54 (39.4) | 48 (33.1) | 37 (28.0) | 27 (19.4) | 31 (24.0) | 35 (25.9) | 28 (22.4) |
Missing | 2 (1.4) | 0 (0) | 10 (6.9) | 10 (7.6) | 17 (12.2) | 14 (10.8) | 23 (17.0) | 19 (15.2) |
Usual activities, n (%) | ||||||||
No problems | 40 (27.4) | 38 (27.7) | 48 (33.1) | 30 (22.7) | 38 (27.3) | 31 (24.0) | 38 (28.15) | 29 (23.2) |
Moderate problems | 66 (45.2) | 54 (39.4) | 57 (39.3) | 61 (46.2) | 61 (43.9) | 59 (45.7) | 51 (37.8) | 52 (41.6) |
Extreme problems | 40 (27.4) | 45 (32.9) | 30 (20.7) | 31 (23.5) | 23 (16.6) | 24 (18.6) | 23 (17.0) | 25 (20.0) |
Reporting some problemsa | 106 (71.6) | 99 (72.3) | 87 (60.0) | 92 (69.7) | 84 (60.4) | 83 (64.3) | 74 (54.8) | 77 (61.6) |
Missing | 2 (1.4) | 0 (0) | 10 (6.9) | 10 (7.6) | 17 (12.2) | 15 (11.6) | 23 (17.0) | 19 (15.2) |
Pain/discomfort, n (%) | ||||||||
No problems | 48 (32.9) | 52 (38.0) | 43 (29.7) | 48 (36.4) | 45 (32.4) | 34 (26.4) | 32 (23.7) | 29 (23.2) |
Moderate problems | 80 (54.8) | 66 (48.2) | 77 (53.1) | 60 (45.5) | 61 (43.9) | 60 (46.5) | 63 (46.7) | 59 (47.2) |
Extreme problems | 18 (12.3) | 19 (13.4) | 15 (10.3) | 14 (10.6) | 16 (11.5) | 20 (15.5) | 17 (12.6) | 18 (14.4) |
Reporting some problemsa | 98 (66.2) | 85 (62.0) | 92 (63.5) | 74 (56.1) | 77 (55.4) | 80 (62.0) | 80 (59.3) | 77 (61.6) |
Missing | 2 (1.4) | 0 (0) | 10 (6.9) | 10 (7.6) | 17 (12.2) | 15 (11.6) | 23 (17.0) | 19 (15.2) |
Anxiety/depression, n (%) | ||||||||
No problems | 96 (65.8) | 76 (55.5) | 86 (59.3) | 78 (59.1) | 75 (54.0) | 64 (49.6) | 70 (51.9) | 65 (52.0) |
Moderate problems | 42 (28.8) | 50 (36.5) | 44 (30.3) | 37 (28.0) | 44 (31.7) | 44 (34.1) | 38 (28.2) | 36 (28.8) |
Extreme problems | 8 (5.5) | 11 (8.0) | 5 (3.5) | 6 (4.6) | 3 (2.2) | 6 (4.7) | 4 (3.0) | 4 (3.2) |
Reporting some problemsa | 50 (33.8) | 61 (44.5) | 49 (33.8) | 43 (32.6) | 47 (33.8) | 50 (38.8) | 42 (31.1) | 40 (32.0) |
Missing | 2 (1.4) | 0 (0) | 11 (8.3) | 10 (7.6) | 17 (12.2) | 15 (11.6) | 23 (17.0) | 20 (16.0) |
Any dimension, n (%) | ||||||||
No problems | 11 (7.4) | 12 (8.8) | 14 (9.7) | 12 (9.1) | 15 (10.8) | 8 (6.2) | 7 (5.2) | 9 (7.2) |
Moderate problems | 79 (53.4) | 64 (46.7) | 78 (53.8) | 68 (51.5) | 69 (49.6) | 70 (54.3) | 68 (50.4) | 61 (48.8) |
Extreme problems | 56 (37.8) | 61 (44.5) | 43 (29.7) | 42 (31.8) | 38 (27.3) | 38 (29.5) | 37 (27.4) | 36 (28.8) |
Reporting some problemsa | 135 (91.2) | 125 (91.2) | 121 (83.5) | 110 (83.3) | 107 (77.0) | 108 (83.7) | 105 (77.8) | 97 (77.6) |
Missing | 2 (1.4) | 0 (0) | 10 (6.9) | 10 (7.6) | 17 (12.2) | 13 (10.1) | 23 (17.0) | 19 (15.2) |
EQ-5D-3L index scoreb | 0.518 | 0.472 | 0.550 | 0.544 | 0.558 | 0.505 | 0.495 | 0.482 |
EQ-VAS scoreb | 59.16 | 55.51 | 59.49 | 59.12 | 61.20 | 58.62 | 60.44 | 56.92 |
Mobility | Self-care | Usual activities | Pain/Discomfort | Anxiety/Depression | ||||||
---|---|---|---|---|---|---|---|---|---|---|
OR (95% CI) | p-value | OR (95% CI) | p-value | OR (95% CI) | p-value | OR (95% CI) | p-value | OR (95% CI) | p-value | |
Constant | 0.02 (0.00–5.08) | 0.167 | 0.12 (0.02–0.57) | 0.008 | 0.01 (0.00–2.27) | 0.099 | 0.54 (0.28–1.06) | 0.167 | 45.09 (0.23–89.84) | 0.159 |
Intervention group | 0.72 (0.35–1.47) | 0.365 | 1.25 (0.66–2.34) | 0.437 | 0.86 (0.44–1.67) | 0.656 | 1.18 (0.71–1.94) | 0.525 | 0.69 (0.34–1.41) | 0.312 |
Time (reference: discharge) | ||||||||||
1 month | 0.75 (0.43–1.30) | 0.306 | 0.78 (0.47–1.28) | 0.318 | 0.82 (0.48–1.41) | 0.467 | 0.99 (0.64–1.53) | 0.960 | 0.81 (0.49–1.35) | 0.433 |
6 months | 1.12 (0.63–1.98) | 0.707 | 0.39 (0.23–0.67) | 0.001 | 1.02 (0.59–1.79) | 0.081 | 1.13 (0.72–1.77) | 0.593 | 1.36 (0.81–2.28) | 0.242 |
12 months | 1.73 (0.95–3.16) | 0.075 | 0.78 (0.46–1.34) | 0.366 | 1.08 (0.62–1.90) | 0.784 | 1.69 (1.05–2.71) | 0.031 | 1.07 (0.63–1.82) | 0.797 |
Study ward 1 | NS | 2.42 (1.04–5.66) | 0.041 | 3.27 (1.43–7.47) | 0.005 | NA | NS | |||
Age when includeda | 1.08 (1.02–1.15) | 0.010 | NS | 1.08 (1.02–1.14) | 0.013 | NA | 0.93 (0.87–0.99) | 0.025 | ||
Sex Female | NA | NA | NS | 2.04 (1.22–3.40) | 0.007 | 2.59 (1.24–5.41) | 0.011 | |||
Level of education > 12 years | NA | NA | NS | NA | NA | |||||
Home-dwelling before included | 0.07 (0.01–0.46) | 0.006 | 0.12 (0.03–0.42) | 0.001 | 0.03 (0.00–0.22) | 0.001 | NA | NS | ||
Living alone before included | NS | NS | NS | NA | NA | |||||
Home-care services | 6.79 (2.95–15.64) | < 0.001 | 12.44 (5.71–27.10) | < 0.001 | 4.77 (2.18–10.43) | < 0.001 | NS | NS | ||
Number of medications totala | 1.11 (1.02–1.20) | 0.012 | 1.10 (1.03–1.17) | 0.003 | 1.24 (1.14–1.34) | < 0.001 | 1.12 (1.07–1.18) | < 0.001 | 1.09 (1.01–1.17) | 0.023 |
Handling own medications | NS | NS | NS | NA | 0.34 (0.15–0.76) | 0.009 | ||||
Multidose adherence aid | NS | NS | NS | NS | NS | |||||
Hypertension | NA | NA | NA | NA | NA | |||||
Asthma or COPD | NA | NS | NS | NS | NA | |||||
Atrial fibrillation | NS | NS | NS | NA | 2.58 (1.17–5.70) | 0.019 | ||||
Diabetes | NS | NS | NS | NA | NS | |||||
Heart failure | NS | NS | 0.36 (0.13–0.97) | 0.043 | NA | NS | ||||
Renal failure | NA | NA | NA | NA | NA | |||||
Anxiety / depression | NA | NS | NS | NS | 19.94 (5.35–74.39) | < 0.001 | ||||
Dementia | NA | NS | NA | 0.15 (0.28–0.06) | 0.007 | NA | ||||
Charlson Comorbidity Indexb | NS | NS | NS | NA | NA |
EQ-5D-3L index scores
Univariable regression | Multivariable regression | |||
---|---|---|---|---|
β (95% CI) | p-value | β (95% CI) | p-value | |
Constant | 0.51 (0.39–0.10) | < 0.001 | 0.80 (0.39–1.20) | < 0.001 |
Intervention group | 0.04 (−0.03–0.10) | 0.293 | 0.007 (–) | 0.791 |
Time (reference: discharge) | ||||
1 month | 0.02 (−0.02–0.06) | 0.396 | 0.02 (−0.02–0.06) | 0.387 |
6 months | −0.01 (−0.06–0.03) | 0.484 | −0.02 (−0.06–0.03) | 0.473 |
12 months | −0.06 (−0.10–−0.02) | 0.003 | −0.06 (−0.10–−0.02) | 0.003 |
Study ward 1 | −0.17 (−0.25–−0.09) | < 0.001 | NS | |
Age when includeda | −0.01 (−0.02–−0.01) | < 0.001 | −0.003 (0.155–) | 0.229 |
Sex Female | −0.06 (−0.13–0.01) | 0.114 | NS | |
Level of education > 12 years | 0.02 (−0.05–0.09) | 0.612 | NA | |
Home-dwelling before included | 0.20 (0.07–0.34) | 0.003 | 0.22 (0.11–0.33) | < 0.001 |
Living alone before included | −0.03 (−0.10–0.04) | 0.380 | NA | |
Home-care services | −0.26 (−0.32–−0.20) | < 0.001 | −0.15 (−0.21–−0.08) | < 0.001 |
Number of medications totala | −0.03 (−0.03–−0.02) | < 0.001 | −0.02 (−0.02–−0.01) | < 0.001 |
Handling own medications | 0.25 (0.19–0.31) | < 0.001 | NS | NS |
Multidose adherence aid | −0.26 (−0.33–−0.19) | < 0.001 | −0.11 (−0.18–−0.04) | < 0.001 |
Hypertension | 0.005 (-0.07–0.06) | 0.894 | NA | |
Asthma or COPD | −0.09 (−0.16–−0.01) | 0.021 | NS | |
Atrial fibrillation | −0.04 (−0.11–0.04) | 0.318 | NA | |
Diabetes | −0.09 (−0.17–−0.00) | 0.040 | NS | |
Heart failure | −0.08 (−0.18–0.01) | 0.086 | NS | |
Renal failure | −0.02 (−0.12–0.07) | 0.630 | NA | |
Anxiety / depression | −0.15 (−0.27–−0.39) | 0.009 | NS | |
Dementia | −0.17 (−0.34–0.01) | 0.059 | NS | |
Charlson Comorbidity Indexb | −0.03 (−0.05–−0.02) | < 0.001 | NS |
EQ-VAS
Univariable regression | Multivariable regression | |||
---|---|---|---|---|
β (95% CI) | p-value | β (95% CI) | p-value | |
Constant | 58.34 (50.81–65.89) | < 0.001 | 98.00 (74.04–121.70) | < 0.001 |
Intervention group | 3.16 (−0.69–7.00) | 0.108 | 2.06 (−1.38–5.50) | 0.241 |
Time (reference: discharge) | ||||
1 month | 1.70 (−0.85–4.25) | 0.191 | 1.35 (−1–20–3.90) | 0.300 |
6 months | 2.29 (−0.36–4.93) | 0.090 | 1.84 (−0.80–4.48) | 0.171 |
12 months | 0.99 (−1.81–3.78) | 0.489 | 0.41 (−2.39–3.20) | 0.776 |
Study ward 1 | −10.35 (−14.83–−5.88) | < 0.001 | −6.50 (−10.78–−2.22) | 0.003 |
Age when includeda | −0.67 (−0.98–−0.35) | < 0.001 | −0.32 (−0.62–−0.01) | 0.040 |
Sex Female | −1.94 (−6.001–2.12) | 0.348 | NA | |
Level of education > 12 years | 1.00 (−3.07–5.07) | 0.631 | NA | |
Home-dwelling before included | 7.04 (−1.54–15.62) | 0.108 | NS | |
Living alone before included | −3.34 (−7.54–0.46) | 0.083 | NS | |
Home-care services | −10.57 (−14.34–−6.81) | < 0.001 | −3.99 (−7.87–−0.11) | 0.044 |
Number of medications totala | −1.20 (−1.53–−0.86) | < 0.001 | −1.00 (−1.32–−0.66) | < 0.001 |
Handling own medications | 8.83 (4.96–12.70) | < 0.001 | NS | |
Multidose adherence aid | −10.75 (−14.98–−6.52) | < 0.001 | NS | |
Hypertension | 1.35 (−2.62–5.32) | 0.506 | NA | |
Asthma or COPD | −2.61 (−6.91–1.70) | 0.235 | NS | |
Atrial fibrillation | −3.60 (−8.13–0.92) | 0.119 | NS | |
Diabetes | −3.74 (−8.59–1.11) | 0.131 | NS | |
Heart failure | −8.27 (−13.86–−2.67) | 0.004 | NS | |
Renal failure | −1.57 (−6.95–3.81) | 0.567 | NA | |
Anxiety / depression | −5.48 (−12.46–1.49) | 0.123 | NS | |
Dementia | −1.98 (−14.58–10.62) | 0.758 | NS | |
Charlson Comorbidity Indexb | −1.17 (−2.19–−0.16) | 0.023 | NS |